Federal regulators have issued a stark warning to more than 350 medical practices that Botox they may have received from a Canadian supplier is counterfeit, unsafe, and unapproved.
Letters sent out from the Food and Drug Administration last month — and made public this week — said shipments of the wrinkle treatment owned by the pharmacy “Canada Drugs” are not FDA approved and that the agency couldn’t guarantee their effectiveness or safety.
According to the Associated Press, the FDA also said “Canada Drugs” had previously been linked to the shipping of unapproved and counterfeit cancer drugs.
The agency has advised doctors to buy drugs from licensed US pharmacies only and to be cautious about using foreign suppliers who may be stocking unapproved drugs, the Montana Standard reports.
This is not the first time the FDA has stepped in to warn medical centers.
In February, the agency contacted 19 medical practices to tell them they had received a counterfeit version of the cancer drug Avastin.
Similar warnings had previously been issued concerning Altuzan, an alternative brand name for Avastin. The warnings were mainly targeted at drugs distributed by “Canada Drugs,” said the Associated Press.
In October, the agency ordered around 4,100 websites to stop selling unapproved medications to US consumers. Alarmingly, the majority of those sites wee operated by “Canada Drugs.”
This is the fifth warning the agency has been forced to issue this year about foreign suppliers providing unapproved drugs, the Montana Standard notes.
As yet there had been no public comment from “Canada Drugs.”